

Petition to Make Special

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450**

Appl No.:	Not yet assigned	Confirmation No. Not yet assigned
Applicant:	Alan Zamore	
Filed:	Concurrently Herewith	
TC/A.U.:	Not yet assigned	
Examiner:	Not yet assigned	

Docket No.: 2003-6
Customer No.: 23401



23401

PATENT TRADEMARK OFFICE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**PETITION TO MAKE SPECIAL UNDER 37 CFR § 1.102
AND SUPPORTING STATEMENT**

Dear Sir:

Applicant hereby petitions the Commissioner of Patents and Trademarks to make the above referenced application special on the grounds that:

1. A statement establishing small entity status is included; and
2. A statement by the applicant is also included wherein applicant states that: (a) the subject of the patent application is a major asset of the small entity, and (b) the development of the technology will be significantly impaired if examination of the patent application is delayed, and also includes an explanation of the basis for making the statement.

Respectfully submitted,

By 
Alan Zamore

10/31/2003 BABRAH1 00000057 10688292

04 FC:1460

130.00 OP

STATEMENT IN SUPPORT OF PETITION TO MAKE SPECIAL

I, Alan Zamore, hereby state the following:


1. I am the president of Zylon Corporation.
2. Zylon Corporation is the sole owner of the presently filed U.S. patent application titled "Reduced Profile Medical Balloon Element" filed on August 16, 2003 ("Patent Application").
3. Zylon Corporation is a small entity as evidenced by the accompanying small entity statement.
4. The subject of the Patent Application a major asset of Zylon Corporation.
5. The development of the technology of the present patent application will be significantly impaired if examination of the Patent Application is delayed as funds for development of the technology are contingent on examination not being delayed:

Based on earlier communications, prospective investors for the claimed technology will only provide material support upon accelerated examination. The field of medical devices in the area of angioplasty currently experiences rapid growth at limited funding availability. Funding is generally only provided when the USPTO has issued a first office action that will allow at least some perspective on patentability and scope of the pending claims. It is therefore my and my investors' belief that Zylon Corporation can only continue development of the claimed technology if the present application is examined on an expedited basis.

Respectfully submitted,

Zylon Corporation

By



Alan Zamore
President